Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer

M. Clerici, F. De Marinis, E. Piazza, L. Frontini, E. Tucci, S. Barni, S. Bretti, G. Luporini, C. Intini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC). Method: Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values. Results: A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39%). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40% and 14%, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia. Conclusions: This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.

Original languageEnglish
Pages (from-to)669-672
Number of pages4
JournalTumori
Volume84
Issue number6
Publication statusPublished - 1998

Fingerprint

Epirubicin
Non-Small Cell Lung Carcinoma
Cisplatin
Karnofsky Performance Status
Asthenia
Mucositis
Poisons
Leukopenia
Anorexia
Granulocyte Colony-Stimulating Factor
Nausea
Vomiting
Intercellular Signaling Peptides and Proteins
Hemoglobins
Outpatients
Therapeutics

Keywords

  • Chemotherapy
  • Cisplatin
  • Epirubicin
  • High-dose chemotherapy
  • NSCLC

ASJC Scopus subject areas

  • Cancer Research

Cite this

Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer. / Clerici, M.; De Marinis, F.; Piazza, E.; Frontini, L.; Tucci, E.; Barni, S.; Bretti, S.; Luporini, G.; Intini, C.

In: Tumori, Vol. 84, No. 6, 1998, p. 669-672.

Research output: Contribution to journalArticle

Clerici, M, De Marinis, F, Piazza, E, Frontini, L, Tucci, E, Barni, S, Bretti, S, Luporini, G & Intini, C 1998, 'Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer', Tumori, vol. 84, no. 6, pp. 669-672.
Clerici, M. ; De Marinis, F. ; Piazza, E. ; Frontini, L. ; Tucci, E. ; Barni, S. ; Bretti, S. ; Luporini, G. ; Intini, C. / Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer. In: Tumori. 1998 ; Vol. 84, No. 6. pp. 669-672.
@article{53758e40e8b346ceab203f67ac06f773,
title = "Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer",
abstract = "Aim: To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC). Method: Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values. Results: A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39{\%}). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40{\%} and 14{\%}, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia. Conclusions: This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.",
keywords = "Chemotherapy, Cisplatin, Epirubicin, High-dose chemotherapy, NSCLC",
author = "M. Clerici and {De Marinis}, F. and E. Piazza and L. Frontini and E. Tucci and S. Barni and S. Bretti and G. Luporini and C. Intini",
year = "1998",
language = "English",
volume = "84",
pages = "669--672",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer

AU - Clerici, M.

AU - De Marinis, F.

AU - Piazza, E.

AU - Frontini, L.

AU - Tucci, E.

AU - Barni, S.

AU - Bretti, S.

AU - Luporini, G.

AU - Intini, C.

PY - 1998

Y1 - 1998

N2 - Aim: To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC). Method: Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values. Results: A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39%). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40% and 14%, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia. Conclusions: This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.

AB - Aim: To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC). Method: Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values. Results: A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39%). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40% and 14%, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia. Conclusions: This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.

KW - Chemotherapy

KW - Cisplatin

KW - Epirubicin

KW - High-dose chemotherapy

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=0032460548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032460548&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 669

EP - 672

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -